Novavax NVAX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $139.51M-79.1% | $147.14M+66.6% | $70.45M-16.6% | $239.24M-42.4% | $666.66M+610% | ||
| $30.7M+117% | $22.1M-39.7% | $21.5M-64.5% | $15.33M-66.9% | $14.12M-76.2% | ||
| $108.82M-83.3% | $125.04M+142% | $48.95M+105% | $223.92M-39.4% | $652.54M+1,783% | ||
| 78%-19.9pp | 85%+26.5pp | 69.5%+41.2pp | 93.6%+4.7pp | 97.9%+61.0pp | ||
| $95.47M+7.3% | $75.88M-27.3% | $98.27M+12.7% | $79.23M-25.9% | $88.94M-4.0% | ||
| $28.78M-40.2% | $34.12M-56.4% | $31.66M-55.3% | $43.61M— | $48.09M— | ||
| $154.94M+2.5% | $132.91M-39.4% | $248.46M+13.7% | $138.17M-45.7% | $151.14M-36.7% | ||
| -$15.43M-103% | $14.23M+111% | -$178.02M-32.8% | $101.07M-37.2% | $515.51M+456% | ||
| -11.1%-88.4pp | 9.7%+158pp | -252.7%-94.1pp | 42.2%+3.5pp | 77.3%+232pp | ||
| $4.9M-14.4% | $5.82M-23.2% | $5.48M+29.4% | $5.52M+33.2% | $5.72M+39.2% | ||
| $11.83M+17.6% | $9.5M-27.7% | $9.18M-42.4% | $11.9M+54.0% | $10.06M+175% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$8.51M-102% | $17.9M+124% | -$203.04M-66.0% | $107.45M-34.7% | $519.85M+458% | ||
| $985K-17.9% | $376K-95.0% | -$657K+36.3% | $946K-57.1% | $1.2M-46.9% | ||
| -$9.49M-102% | $17.53M+122% | -$202.38M-66.8% | $106.51M-34.4% | $518.65M+452% | ||
| -6.8%-84.6pp | 11.9%+104pp | -287.3%-144pp | 44.5%+5.4pp | 77.8%+235pp | ||
| -$0.06-102% | $0.05+110% | -$1.25-64.5% | $0.62-37.4% | $2.93+379% | ||
| -$0.06-102% | $0.11+121% | -$1.25-64.5% | $0.66-39.4% | $3.22+407% | ||
| 163.3M-8.1% | 173.1M+13.7% | 162.4M+1.4% | 177.2M+6.8% | 177.6M+27.0% | ||
| 163.3M+1.4% | 162M+6.4% | 162.4M+1.4% | 162M+9.2% | 161M+15.1% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $11.83M+17.6% | $9.5M-27.7% | $9.18M-42.4% | $11.9M+54.0% | $10.06M+175% | ||
| -$15.43M-103% | $14.23M+111% | -$178.02M-32.8% | $101.07M-37.2% | $515.51M+456% | ||
| -$12.37M-102% | $19.36M+116% | -$171.43M-41.3% | $108.63M-36.9% | $523.85M+495% | ||
| -$12.37M-102% | $19.36M+116% | -$171.43M-41.3% | $108.63M-36.9% | $523.85M+495% | ||
| -8.9%-87.4pp | 13.2%+147pp | -243.4%-99.8pp | 45.4%+4.0pp | 78.6%+220pp | ||
| -$15.43M-103% | $14.23M+111% | -$178.02M-32.8% | $101.07M-37.2% | $515.51M+456% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Novavax's revenue?
- Novavax (NVAX) generated $596.3M in revenue over the trailing twelve months, down 52.5% year over year.
- Is Novavax profitable?
- Novavax is not currently profitable: it reported a net loss of $87.8M over the trailing twelve months, a -14.7% net margin.
- What are Novavax's profit margins?
- Gross margin is 85.0% and operating margin is -13.1%, with a -14.7% net margin.
- What is Novavax's earnings per share?
- Novavax's diluted EPS over the trailing twelve months is $-0.64.
- Where does Novavax's income statement data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
